University of New South Wales, Sydney, NSW, Australia.
Department of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Acta Anaesthesiol Scand. 2018 Oct;62(9):1321-1326. doi: 10.1111/aas.13159. Epub 2018 May 24.
Corticosteroids are frequently prescribed to critically ill patients. However, their use may increase the risk of gastrointestinal (GI) bleeding, which is associated with morbidity and mortality. Accordingly, we aim to assess whether continued administration of corticosteroids for >24 hours increases the rate of GI bleeding in adult critically ill patients compared to placebo or no treatment.
METHODS/DESIGN: We will conduct a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis. The participants will be adult (as defined in the included trials) critically ill patients. The intervention will be any corticosteroid administered systematically for >24 hours and the comparator will be placebo or no treatment. The primary outcome will be rate of clinically important GI bleeding. We will systematically search EMBASE, MEDLINE, Medline In-Process, Cochrane Library, Epistemonikos and trial registries for relevant literature, as well as perform a hand search. We will follow the recommendations by the Cochrane Collaboration and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. The risk of systematic errors (bias) and random errors will be assessed and the overall quality of evidence will be evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
The risk of GI bleeding in adult critically ill patients treated with corticosteroids is unknown. Hence, there is need for a robust systematic review to assess this risk and provide clinicians with a clearer understanding of the strength and limitations of existing data.
皮质类固醇经常被开给危重症患者。然而,它们的使用可能会增加胃肠道(GI)出血的风险,这与发病率和死亡率有关。因此,我们旨在评估与安慰剂或不治疗相比,皮质类固醇连续给药>24 小时是否会增加成年危重症患者的 GI 出血率。
方法/设计:我们将对随机临床试验进行系统评价,结合荟萃分析和试验序贯分析。参与者将为成年(如纳入试验中所定义)危重症患者。干预措施将是任何系统性给予>24 小时的皮质类固醇,比较组将是安慰剂或不治疗。主要结局将是临床上重要的 GI 出血率。我们将系统地搜索 EMBASE、MEDLINE、Medline In-Process、Cochrane 图书馆、Epistemonikos 和试验登记处的相关文献,并进行手工搜索。我们将遵循 Cochrane 协作组织和系统评价和荟萃分析的首选报告项目(PRISMA)声明的建议。将评估系统误差(偏倚)和随机误差的风险,并使用推荐评估、制定和评估(GRADE)方法评估证据的总体质量。
皮质类固醇治疗的成年危重症患者的 GI 出血风险尚不清楚。因此,需要进行一项稳健的系统评价,以评估这种风险,并使临床医生更清楚地了解现有数据的优势和局限性。